WO2002012345A3 - Soluble zcytor 11 cytokine receptors - Google Patents

Soluble zcytor 11 cytokine receptors Download PDF

Info

Publication number
WO2002012345A3
WO2002012345A3 PCT/US2001/024838 US0124838W WO0212345A3 WO 2002012345 A3 WO2002012345 A3 WO 2002012345A3 US 0124838 W US0124838 W US 0124838W WO 0212345 A3 WO0212345 A3 WO 0212345A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
antibodies
vitro
vivo
cytokine receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/024838
Other languages
French (fr)
Other versions
WO2002012345A2 (en
Inventor
Wayne R Kindsvogel
Stavros Topouzis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Priority to DE60123998T priority Critical patent/DE60123998T2/en
Priority to CA002418950A priority patent/CA2418950A1/en
Priority to AU2001290524A priority patent/AU2001290524A1/en
Priority to JP2002518316A priority patent/JP5015404B2/en
Priority to EP01970531A priority patent/EP1337636B1/en
Publication of WO2002012345A2 publication Critical patent/WO2002012345A2/en
Anticipated expiration legal-status Critical
Publication of WO2002012345A3 publication Critical patent/WO2002012345A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zcytor 11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or developemnt of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides and antibodies can also be used to block TIF activity in vitro and in vivo, and may be used in conjuction with TIF and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
PCT/US2001/024838 2000-08-08 2001-08-08 Soluble zcytor 11 cytokine receptors Ceased WO2002012345A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE60123998T DE60123998T2 (en) 2000-08-08 2001-08-08 SOLUBLE ZCYCTOR 11 CYTOKIN RECEPTORS
CA002418950A CA2418950A1 (en) 2000-08-08 2001-08-08 Soluble zcytor 11 cytokine receptors
AU2001290524A AU2001290524A1 (en) 2000-08-08 2001-08-08 Soluble zcytor 11 cytokine receptors
JP2002518316A JP5015404B2 (en) 2000-08-08 2001-08-08 Soluble ZCYTOR11 cytokine receptor
EP01970531A EP1337636B1 (en) 2000-08-08 2001-08-08 Soluble zcytor 11 cytokine receptors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22382700P 2000-08-08 2000-08-08
US60/223,827 2000-08-08
US25087600P 2000-12-01 2000-12-01
US60/250,876 2000-12-01

Publications (2)

Publication Number Publication Date
WO2002012345A2 WO2002012345A2 (en) 2002-02-14
WO2002012345A3 true WO2002012345A3 (en) 2003-06-12

Family

ID=26918167

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/024838 Ceased WO2002012345A2 (en) 2000-08-08 2001-08-08 Soluble zcytor 11 cytokine receptors

Country Status (9)

Country Link
US (5) US7045498B2 (en)
EP (2) EP2177616B1 (en)
JP (1) JP5015404B2 (en)
AT (2) ATE342980T1 (en)
AU (1) AU2001290524A1 (en)
CA (1) CA2418950A1 (en)
DE (1) DE60123998T2 (en)
ES (1) ES2381650T3 (en)
WO (1) WO2002012345A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
ES2381650T3 (en) * 2000-08-08 2012-05-30 Zymogenetics, Inc. Soluble Zcytor11 cytokine receptors
JP4908723B2 (en) 2000-09-15 2012-04-04 ザイモジェネティクス， インコーポレイテッド Methods for treating inflammation
US7094570B2 (en) 2003-03-11 2006-08-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US7268223B2 (en) * 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
JP2004533811A (en) 2001-01-12 2004-11-11 ジェネティクス インスティテュート，エルエルシー Type 2 cytokine receptor and nucleic acid encoding type 2 cytokine receptor
CA2467723C (en) 2001-12-17 2011-09-27 Zymogenetics, Inc. Method for treating cervical cancer
MXPA05001758A (en) * 2002-08-16 2005-08-19 Wyeth Corp Compositions and methods for treating rage-associated disorders.
CN1845937A (en) * 2003-03-24 2006-10-11 津莫吉尼蒂克斯公司 Anti-IL-20 antibodies and binding partners and methods of use in inflammation
EP1606316A2 (en) 2003-03-24 2005-12-21 ZymoGenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
DE602004023965D1 (en) * 2003-11-21 2009-12-17 Zymogenetics Inc ANTI-IL-20 ANTIBODIES AND BINDING PARTNERS AND METHOD FOR APPLYING TO INFLAMMATIONS
JP4898691B2 (en) 2004-10-22 2012-03-21 ザイモジェネティクス， インコーポレイテッド Anti-IL-22RA antibodies and binding partners and uses in inflammation
WO2006058024A2 (en) * 2004-11-22 2006-06-01 Smith Henry J Cellular receptors used in the treatment of inflammatory disease
EP2192132A3 (en) 2005-02-08 2010-08-18 ZymoGenetics, Inc. Anti-IL-20, anti-IL22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
EP3214095B1 (en) 2005-05-12 2019-12-11 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
US7180469B2 (en) * 2005-06-29 2007-02-20 Cushcraft Corporation System and method for providing antenna radiation pattern control
JP5368301B2 (en) 2006-06-22 2013-12-18 ノボ・ノルデイスク・エー／エス Soluble heterodimeric receptor and uses thereof
EP2158210B1 (en) 2007-06-14 2015-12-09 Galactica Pharmaceuticals, Inc. Rage fusion proteins
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
BR112012021576A2 (en) 2010-02-26 2016-10-25 Novo Nordisk As stable antibody-containing compositions.
RU2012153786A (en) 2010-05-28 2014-07-10 Ново Нордиск А/С STABLE MULTI-DOSE COMPOSITIONS CONTAINING ANTIBODY AND CONSERVANT
AU2012205301B2 (en) 2011-01-14 2017-01-05 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
AU2017257504A1 (en) 2016-04-26 2018-10-25 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
KR20210025054A (en) * 2018-06-21 2021-03-08 샤턱 랩스 인코포레이티드 Heterodimeric proteins and uses thereof
JP7743500B2 (en) * 2020-08-05 2025-09-24 シンセカイン インコーポレイテッド IL10 receptor binding molecules and methods of use
WO2022032045A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. IL10Rα/IL2Rγ SYNTHETIC CYTOKINES
US12454572B2 (en) 2021-03-02 2025-10-28 Dana-Farber Cancer Institute, Inc. Methods of treating anemia in myelodysplastic syndromes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007848A1 (en) * 1997-08-05 1999-02-18 Zymogenetics, Inc. Mammalian cytokine receptor-11
WO2000039161A1 (en) * 1998-12-31 2000-07-06 Millennium Pharmaceuticals, Inc. Class ii cytokine receptor-like proteins and nucleic acids encoding them
WO2001016318A2 (en) * 1999-09-01 2001-03-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
WO1989004838A1 (en) * 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5436155A (en) 1991-12-31 1995-07-25 Arch Development Corporation Isolated DNA encoding a somatostatin receptor
US5789192A (en) 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
WO1998002540A1 (en) * 1996-07-12 1998-01-22 Genentech, Inc. Chimeric heteromultimer adhesins
US5843697A (en) * 1996-07-17 1998-12-01 University Of Medicine And Dentistry Of New Jersey Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein
US5985614A (en) 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU8571198A (en) 1997-07-16 1999-02-10 Human Genome Sciences, Inc. Interleukin-20
US6486301B1 (en) 1997-07-16 2002-11-26 Human Genome Sciences, Inc. Interleukin-20
AU8899298A (en) 1997-08-06 1999-03-01 Zymogenetics Inc. Lipocalin homologs
US6576743B1 (en) 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
CN1247780C (en) 1997-11-26 2006-03-29 津莫吉尼蒂克斯公司 mammalian cytokine-like polypeptide-10
EP1047781B1 (en) 1998-01-23 2004-07-28 Immunex Corporation Il-18 receptors
WO1999046379A2 (en) 1998-03-09 1999-09-16 Schering Corporation Human receptor proteins; related reagents and methods
JP3868740B2 (en) 1998-03-10 2007-01-17 ジェネンテック・インコーポレーテッド Novel polypeptide and nucleic acid encoding the same
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
AU5203199A (en) 1998-05-26 1999-12-13 Procter & Gamble Company, The Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
EP1100830B1 (en) * 1998-07-28 2003-10-01 Micromet AG Heterominibodies
NZ531664A (en) 1998-09-01 2005-07-29 Genentech Inc Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
EP1131333B1 (en) 1998-10-26 2010-06-02 Wyeth a Corporation of the State of Delaware ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE T CELL INDUCIBLE FACTORS (TIFs), THE PROTEINS ENCODED, AND USES THEREOF
US6274710B1 (en) 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
BR0010097A (en) 1999-04-28 2002-02-13 Genetics Inst Isolated polynucleotide; host cell; process for the production of a protein encoded by the polynucleotide; protein; composition; and; antibody
WO2000070049A2 (en) 1999-05-19 2000-11-23 Incyte Genomics, Inc. Extracellular signaling molecules
AU5047600A (en) 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
ATE448246T1 (en) 1999-06-15 2009-11-15 Genentech Inc SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS FOR THE ENCODING THEM
CA2378519C (en) 1999-07-07 2011-01-25 Zymogenetics, Inc. Human cytokine receptor
MXPA02005058A (en) 1999-11-18 2002-11-07 Schering Corp Mammalian receptor proteins; related reagents and methods.
US6897292B2 (en) * 1999-12-03 2005-05-24 Zymogenetics, Inc. Human cytokine receptor
WO2001046261A1 (en) 1999-12-23 2001-06-28 Zymogenetics, Inc. Method for treating inflammation
JP4741139B2 (en) 1999-12-23 2011-08-03 ザイモジェネティクス， インコーポレイテッド Soluble interleukin-20 receptor
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
DE60043944D1 (en) 1999-12-23 2010-04-15 Zymogenetics Inc ZYTOKIN ZCYT018
NZ523122A (en) 2000-06-22 2004-06-25 Smithkline Beecham Corp Polypeptides and polynucleotides and methods of identifying agonists and antagonists in relation to treatment of diseases
ES2381650T3 (en) * 2000-08-08 2012-05-30 Zymogenetics, Inc. Soluble Zcytor11 cytokine receptors
JP2004509617A (en) 2000-09-08 2004-04-02 シェーリング　コーポレイション Mammalian genes; related reagents and methods
JP4908723B2 (en) 2000-09-15 2012-04-04 ザイモジェネティクス， インコーポレイテッド Methods for treating inflammation
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US20030022827A1 (en) 2000-09-25 2003-01-30 Bertram Weiss Three new members of the cytokine receptor family class 2
JP2004533811A (en) 2001-01-12 2004-11-11 ジェネティクス インスティテュート，エルエルシー Type 2 cytokine receptor and nucleic acid encoding type 2 cytokine receptor
EP1390060A2 (en) 2001-01-26 2004-02-25 Eli Lilly And Company Use of lp82 to treat body weight disorders
MXPA03007413A (en) 2001-02-23 2003-11-18 Inst Genetics Llc Composition and method for treating inflammatory disorders.
WO2002070001A2 (en) 2001-02-28 2002-09-12 Eli Lilly And Company Use of lp82 to treat hematopoietic disorders
JP2004532624A (en) 2001-03-02 2004-10-28 ザイモジェネティクス，インコーポレイティド Mouse cytokine receptor
US20040086908A1 (en) 2002-03-07 2004-05-06 Chandrasekher Yasmin A. Soluble heterodimeric cytokine receptor
AU2002245652A1 (en) 2001-03-09 2002-09-24 Zymogenetics, Inc. Soluble heterodimeric cytokine receptor
US20030099608A1 (en) 2001-03-27 2003-05-29 Presnell Scott R. Human cytokine receptor
US20040204351A1 (en) 2001-10-22 2004-10-14 Rowlinson Scott William Soluble proteins that inhibit cytokine signal transduction pathways
DE10154579A1 (en) 2001-11-07 2003-05-28 Medigene Ag Topical use of cytokines and chemokines for the treatment of viral or mycotic skin diseases or tumors
CA2467723C (en) 2001-12-17 2011-09-27 Zymogenetics, Inc. Method for treating cervical cancer
US20040236075A1 (en) 2002-07-24 2004-11-25 Laure Dumoutier Novel glass II cytokine receptors, and uses thereof
EP1606316A2 (en) 2003-03-24 2005-12-21 ZymoGenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
DE602004023965D1 (en) 2003-11-21 2009-12-17 Zymogenetics Inc ANTI-IL-20 ANTIBODIES AND BINDING PARTNERS AND METHOD FOR APPLYING TO INFLAMMATIONS
JP4898691B2 (en) 2004-10-22 2012-03-21 ザイモジェネティクス， インコーポレイテッド Anti-IL-22RA antibodies and binding partners and uses in inflammation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007848A1 (en) * 1997-08-05 1999-02-18 Zymogenetics, Inc. Mammalian cytokine receptor-11
WO2000039161A1 (en) * 1998-12-31 2000-07-06 Millennium Pharmaceuticals, Inc. Class ii cytokine receptor-like proteins and nucleic acids encoding them
WO2001016318A2 (en) * 1999-09-01 2001-03-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLUMBERG H ET AL: "INTERLEUKIN 20: DISCOVERY, RECEPTOR IDENTIFICATION, AND ROLE IN EPIDERMAL FUNCTION", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 104, 12 January 2001 (2001-01-12), pages 9 - 19, XP000996379, ISSN: 0092-8674 *
DUMOUTIER L ET AL: "Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 166, no. 12, 15 June 2001 (2001-06-15), pages 7090 - 7095, XP002206182, ISSN: 0022-1767 *
XIE M-H ET AL: "Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 275, no. 40, 6 October 2000 (2000-10-06), pages 31335 - 31339, XP002164307, ISSN: 0021-9258 *
XU WENFENG ET AL: "A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 98, no. 17, 14 August 2001 (2001-08-14), pages 9511 - 9516, XP002186667, ISSN: 0027-8424 *
ZHANG ET AL: "Identification, purification, and characterization of a soluble Interleukin (IL)-13 binding protein", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 272, no. 14, 4 April 1997 (1997-04-04), pages 9474 - 9480, XP002104158, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
EP2177616A1 (en) 2010-04-21
US20060068471A1 (en) 2006-03-30
ATE547525T1 (en) 2012-03-15
AU2001290524A1 (en) 2002-02-18
WO2002012345A2 (en) 2002-02-14
JP2004505641A (en) 2004-02-26
EP1337636A2 (en) 2003-08-27
EP2177616B1 (en) 2012-02-29
DE60123998T2 (en) 2007-09-06
JP5015404B2 (en) 2012-08-29
US20100047168A1 (en) 2010-02-25
CA2418950A1 (en) 2002-02-14
ES2381650T3 (en) 2012-05-30
US20110081344A1 (en) 2011-04-07
US20030157096A1 (en) 2003-08-21
EP1337636B1 (en) 2006-10-18
ATE342980T1 (en) 2006-11-15
US7045498B2 (en) 2006-05-16
DE60123998D1 (en) 2006-11-30
US8287866B2 (en) 2012-10-16
US20130028894A1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
WO2002012345A3 (en) Soluble zcytor 11 cytokine receptors
WO2001077171A3 (en) Soluble zalpha11 cytokine receptors
IL163067A (en) Isolated heterodimeric cytokine receptor
UA84387C2 (en) Human cytokine as a ligand of zalpha receptor and use thereof
WO2002000721A3 (en) Cytokine receptor zcytor17
WO2003060090A3 (en) Novel cytokine zcytor17 ligand
WO2002044209A3 (en) Cytonkine receptor zcytor19
CA2267661A1 (en) Variants of vascular endothelial cell growth factor having antagonistic properties
EP1555318A3 (en) Hematopoietic cytokine receptor
OA09704A (en) Antibody antagonist of human interleukin-4.
IL100343A0 (en) G protein coupled glutamate receptors
WO2000017235A3 (en) Cytokine receptor zalpha11
WO2003089603A3 (en) Cytokine receptor
TW272197B (en)
ES2192199T3 (en) LIGANDOS OF THE EPH BIOLOGICALLY ACTIVE FAMILY.
EP1736545A3 (en) Soluble zcytor 11 cytokine receptors
WO2003033665A3 (en) Secreted protein, ztnf9
WO1992016623A3 (en) Receptors for bombesin-like peptides
UA84540C2 (en) Novel cytokine zcytor17 ligand

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2418950

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002518316

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001970531

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001970531

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001970531

Country of ref document: EP